Kajian Literatur: Efektivitas Asetilsistein Dosis Tinggi Pada Pasien PPOK

https://doi.org/10.22146/farmaseutik.v21i3.93852

Sri Rahmat Molidia(1), Dewa Putu Pramantara(2), Zullies Ikawati(3*)

(1) Faculty of Pharmacy, Universitas Gadjah Mada
(2) Department of Internal Medicine, Dr. Sardjito Hospital
(3) Department of Pharmacology, Faculty of Pharmacy, Universitas Gadjah Mada
(*) Corresponding Author

Abstract


Penyakit paru obstruktif kronik (PPOK) merupakan penyebab utama mortalitas dan morbiditas di seluruh dunia, ditandai dengan keterbatasan aliran udara yang persisten, hipersekresi mukus, stres oksidatif, dan inflamasi saluran napas. Asetilsistein memiliki sifat antioksidan dan antiinflamasi, yang telah menunjukkan manfaat bergantung pada dosisnya. Review ini menilai efektivitas dosis tinggi dari asetilsisitein pada pasien PPOK dalam memperbaiki luaran klinis dan frekuensi eksaserbasi. Studi Randomized Control Trial (RCT) dilibatkan dalam kajian literatur ini mengikuti daftar checklist PRISMA. Hasil review dari 6 RCT menunjukkan bahwa pemberian asetilsistein dosis tinggi (>400 mg perhari) secara signifikan dapat menurunkan frekuensi eksaserbasi, memperbaiki fungsi paru (FEV1, FVC, FEV/FVC), perubahan biomarker oksidasi dan inflamasi (Malondialdehid, Glutation, Glutation Peroksida, Cystein, C-Reactive protein). Kesimpulan dari penambahan terapi asetilsistein dosis tinggi mampu menurunkan frekuensi eksaserbasi dan perbaikan klinis secara signifikan dibandingkan plasebo

Keywords


Asetilsistein; PPOK; Efektivitas; Dosis Tinggi

Full Text:

PDF


References

Calverley, P., Rogliani, P., & Papi, A. (2021). Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Drug Safety, 44(3), 273–290. https://doi.org/10.1007/s40264-020-01026-y

Cazzola, M., Rogliani, P., Calzetta, L., Hanania, N. A., & Matera, M. G. (2017). Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 14(5), 552–563. https://doi.org/10.1080/15412555.2017.1347918

De Backer, J., Vos, W., Van Holsbeke, C., Vinchurkar, S., Claes, R., Parizel, P., & De Backer, W. (2013). Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease, 569. https://doi.org/10.2147/COPD.S49307

Fowdar, K., Chen, H., He, Z., Zhang, J., Zhong, X., Zhang, J., Li, M., & Bai, J. (2017). The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review. Heart & Lung, 46(2), 120–128. https://doi.org/10.1016/j.hrtlng.2016.12.004

GOLD. (2022). Pocket Guide to COPD Diagnosis, Management, and Prevention a Guide for Health Care Professionals. Global Initiative for Chronic Obstructive Lung Disease Inc.

Hafiz, A. M. A. E., Wakeel, L. M. E., Hady, H. M. E., & Mourad, A. E. R. (2013). High Dose N-acetylcysteine Improves Inflammatory Response and Outcome in Patients with COPD Exacerbations. Egyptian Journal of Chest Diseases and Tuberculosis, 62(1), 51–57. https://doi.org/10.1016/j.ejcdt.2013.02.012

Huang, C., Kuo, S., Lin, L., & Yang, Y. (2023). The efficacy of N -acetylcysteine in chronic obstructive pulmonary disease patients: A meta-analysis. Therapeutic Advances in Respiratory Disease, 17, 175346662311585. https://doi.org/10.1177/17534666231158563

Johnson, K., Niewoehner, D., McEvoy, C., Naqvi, S., Wendt, C., Reilkoff, R., Kunisaki, K., Wetherbee, E., Nelson, D., & Tirouvanziam, R. (2016). High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: A randomized, placebo-controlled trial. International Journal of Chronic Obstructive Pulmonary Disease, 799. https://doi.org/10.2147/COPD.S102375

Kolarov, V., Stevuljevi, J. K., Ili, M., Bogdan, M., Tušek, B., Agic, A., Dugajli, M., Vereš, K. T., Kutleši, S., & Zvezdin, B. (2022). Factorial Analysis of N-acetylcysteine and Propolis Treatment Effects on Symptoms, Life Quality and Exacerbations in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Randomized, Double-blind, Placebo-controlled Trial. European Review for Medical and Pharmacological Sciences. https://doi.org/10.26355/eurrev_202205_28737

Mahmoudinezhad, M., Abbaszadeh, F., Zarezadeh, M., Bahreini, N., Jamilian, P., Jamilian, P., & Ostadrahimi, A. (2023). N-acetylecysteine, a powerful agent in the reinforcement of anti-oxidant profile: A systematic review and dose-response meta-analysis of controlled clinical trials. Clinical Nutrition ESPEN, 54, 227–238. https://doi.org/10.1016/j.clnesp.2023.01.021

Papi, A., Zheng, J., Criner, G. J., Fabbri, L. M., & Calverley, P. M. A. (2019). Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study. Respiratory Medicine, 147, 37–43. https://doi.org/10.1016/j.rmed.2018.12.014

Tse, H. N., Raiteri, L., Wong, K. Y., Ng, L. Y., Yee, K. S., & Tseng, C. Z. S. (2014). Benefits of High-Dose N-Acetylcysteine to Exacerbation-Prone Patients With COPD. Chest, 146(3), 611–623. https://doi.org/10.1378/chest.13-2784

WHO. (2023). Chronic Obstructive Pulmonary Disease (COPD). World Health Organization. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)



DOI: https://doi.org/10.22146/farmaseutik.v21i3.93852

Article Metrics

Abstract views : 875 | views : 638

Refbacks

  • There are currently no refbacks.


©Majalah Farmaseutik
 ISSN 2406-9086
Faculty of Pharmacy
Universitas Gadjah Mada
 
 
web analytics 

Creative Commons Licence 
 
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License